Boehringer Ingelheim exercises option and acquires global ownership of Pharmaxis’ investigational anti-inflammatory drug candidate PXS4728A, including associated intellectual property rights. Read the full story

Hydra Biosciences and Boehringer Ingelheim have entered into a worldwide research collaboration and license agreement to identify small-molecule TRP inhibitors Read the full story

ARTES Biotechnology announced a collaboration with the global pharmaceutical company Boehringer Ingelheim Animal Health Read the full story

Boehringer Ingelheim has established a research alliance with Vanderbilt University and the cancer drug discovery laboratory Read the full story

Oxford BioTherapeutics announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to an oncology target from an ongoing discovery collaboration Read the full story

BioMed X have entered into a collaboration agreement with Boehringer Ingelheim to establish a research group focusing on the identification of novel therapeutic concepts for treating patients with chronic obstructive pulmonary disease Read the full story

Boehringer Ingelheim and CureVac have entered an exclusive global pharma licensing deal and development partnership to focus on CureVac’s CV9202, netting CureVac $556 million ($45 million upfront). Read the full story

Belgium-based healthcare company Omega Pharma NV is allegedly attracting numerous bids from businesses across the big pharma companies, according to Bloomberg Businessweek. Perrigo and Boehringer Ingelheim GmbH are rumored to be interested in acquiring the company.  Read the full story

Boehringer Ingelheim Vetmedica has secured the pharma licensing rights for the technology platform Artilysin from Lysando. Read the full story